Aeterna Zentaris Inc. Renamed COSCIENS Biopharma Inc.

TORONTO, ONTARIO, Aug. 06, 2024 -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS), a specialized biopharmaceutical enterprise engaged in creating and marketing a wide range of pharmaceutical and diagnostic products as well as active ingredients for the healthcare and cosmetics sectors, has announced a change in its corporate name from "Aeterna Zentaris Inc." to "COSCIENS Biopharma Inc." This change comes into effect on August 6, 2024.

Furthermore, starting August 9, 2024, the company's common shares will trade on the Toronto Stock Exchange (TSX) and NASDAQ Capital Market under the new ticker symbol "CSCI," replacing the former symbol "AEZS."

The name change was approved during the company's annual general and special meeting of shareholders on July 16, 2024, via a special resolution that granted the board of directors the authority to implement the name change. This change is still contingent on final approvals from the TSX and NASDAQ.

There will be no changes in the company's capitalization due to the name change, and current shareholders or warrantholders will not need to take any action. Existing certificates for common shares and warrants will remain valid and do not need to be exchanged. Shareholders and warrantholders are encouraged to reach out to the company or their brokers if they have any questions.

The new CUSIP and ISIN numbers for the common shares are 22112H101 and CA22112H1010, respectively. For the warrants, the new CUSIP number is 22112H119, and the ISIN is CA22112H1192.

COSCIENS Biopharma Inc. is a specialized biopharmaceutical company focused on developing and marketing a diversified portfolio of pharmaceutical and diagnostic products. One of its leading products is macimorelin (Macrilen; Ghryvelin), the only oral test approved by both the U.S. FDA and the European Commission for diagnosing adult growth hormone deficiency (AGHD). The company is also developing therapeutic assets and proprietary extraction technology for producing active ingredients from renewable plant sources. These ingredients are used in cosmeceutical products such as oat beta glucan and avenanthramides, found in popular skincare brands like Aveeno and Burt’s Bees. These ingredients are also being explored for potential nutraceutical and pharmaceutical applications.

The company is listed on both NASDAQ and TSX, currently trading under the symbol "AEZS." However, from August 9, 2024, it will trade under the new symbol "CSCI."

COSCIENS Biopharma Inc. offers a diverse portfolio addressing unmet medical needs and continues to explore new therapeutic avenues and technologies. The company's focus on innovation and dedication to the biopharmaceutical sector positions it as a noteworthy entity in the industry.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!